Biomarkers and Therapeutics

HLS5 LogoThe HLS5 tumour suppressor gene was reported by Professor Klinken's team in 2004.  In conjunction with BPH Energy the expert team at The West Australian Institute for Medical Research (WAIMR) led by Director Professor Peter Klinken are continuing with their research. 

Currently the team will be investigating the tumor suppressor gene HLS5 and its potential influence in Melanoma.  However, the concerted research efforts previously undertaken reveal that HSL5 works through multiple pathways that may target cancer as well as a range of other diseases such as Huntington's, Parkinson's and HIV.

BPH Energy has developed an extensive patent portfolio and has exclusive rights to the tumor suppressor gene HLS5 both as a potential therapeutic target and also underpinning its involvement in a variety of disease pathways.  The patent portfolio of technology surrounding HLS5 is currently going through National Phase filings in Australia, US and Europe.


Partnering | ASX releases | Published Media | Visual Media
Papers | Scientist's Profile | Grants | Current Partners

Email Subscription

Enter your email address below to receive our email updates